Insulin, Time in Range, Type 1 Diabetes
Conditions
Keywords
fast acting insulin, glucometrics
Brief summary
Data on switching from traditional mealtime insulins to fast-acting insulin aspart (Fiasp) in routine clinical practice are sparse. The aim was to evaluate the efficacy and safety of switching from traditional mealtime insulin to Fiasp in a real-world clinical practice setting in people with type 1 diabetes in Belgium.
Detailed description
The primary endpoint was the evolution of time in range (TIR, 70-180 mg/dl) at 6 and 12 months. Secondary endpoints included change in HbA1c, BMI, insulin doses, time below range (T\<70 and T\<54 mg/dl) and time above range (T\>180 and T\>250 mg/dl). Retrospective analysis Two-center study
Interventions
None listed
Sponsors
Universitaire Ziekenhuizen KU Leuven
University Hospital, Antwerp
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Type 1 diabetes patients * Duration of diabetes \> 2 years * Using CGM for \> 6 months
Exclusion criteria
* Using SMBG * Pregnancy * Using glucocorticoids or immunosuppressive agents * Active oncological problem
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time in Range | 12 months | Time in target range at 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in HbA1c | 6 months & 12 months | Change in HbA1c |
| Change in weight | 6 months & 12 months | Change in weight |
| Change in insulin doses | 6 months & 12 months | Change in insulin doses |
| Time in Range | 6 months | Time in target range at 6 months |
| Time above range | 6 months & 12 months | Change in time above range |
| Coefficient of variation | 6 months & 12 months | Change in coefficient of variation |
| Time below range | 6 months & 12 months | Change in time below range |
Countries
Belgium
Outcome results
None listed